About
Leveragen is a Boston-based biotechnology company developing differentiated in vivo platforms for next-generation antibody discovery. Founded in and operating exclusively from Boston, Massachusetts, the company combines advanced genetic engineering, sophisticated antibody model development, and integrated discovery capabilities to support partners across therapeutics, diagnostics, and animal health. Its technologies provide flexible solutions for a broad range of biologic modalities and partner programs.
COMPLEX GENETIC ENGINEERING
Complex genetic engineering is the foundation of Leveragen’s platform innovation. Drawing on expertise in molecular biology, synthetic biology, genetics, genomics, and protein science, the company has built a highly efficient engine for creating sophisticated genetic models that support mechanistic research, preclinical studies, and antibody discovery. This technical depth enables Leveragen to engineer differentiated in vivo systems with the precision and flexibility required for modern biologics development.
Leveragen employs advanced genome engineering approaches to generate complex mouse models ranging from conditional alleles and precise point mutations to large targeted replacements and genomic humanization. The company also applies next-generation genetics approaches to enable direct creation of target gene knockouts without multi-generational breeding. By combining these capabilities with modern mouse production and in vitro fertilization workflows, Leveragen is able to accelerate timelines and deliver precisely engineered models for demanding discovery applications.
FULL-SPeCtRUM ANTIBODY PLATFORMS
Leveragen has developed a broad suite of proprietary antibody discovery platforms designed to address diverse partner needs. Its Singularity Suite, Universality Suite, and Infinity Suite of genetically engineered mouse models span fully human single-domain antibodies, common light chain antibodies, and conventional full-length antibodies. Together, these platforms support a wide range of therapeutic architectures and discovery strategies with a shared focus on diversity, quality, and developability.
At the center of this suite is Singularity Sapiens, Leveragen’s flagship platform for the in vivo discovery of fully human single-domain antibodies. Together with Leveragen’s broader platform portfolio, it enables discovery across multispecific antibodies, antibody-payload conjugates, immune cell engagers, chimeric antigen receptor applications, mRNA-encoded biologics, targeted delivery systems, and other emerging therapeutic formats.
HIGH-THROUGHPUT Discovery
Leveragen pairs its in vivo platforms with a sequence-first, high-throughput discovery engine built to accelerate antibody identification and expand data value. Its integrated workflows span immunization, repertoire capture, phage display, next-generation sequencing, family scanning, hit expansion, recombinant expression, and early developability assessment, allowing programs to move efficiently from immune response to actionable antibody outputs.
This approach supports rapid identification of diverse binders, efficient recovery of rare antibodies, and generation of rich sequence-to-function datasets that strengthen both immediate discovery execution and long-term AI/ML-enabled platform learning.
PARTERNSHIPS and IP
Leveragen is built for partnership. From its Boston base, the company works with biotechnology, pharmaceutical, and academic collaborators globally through flexible engagement models that can include platform licenses, integrated discovery collaborations, and customized commercial structures. Its partnership model emphasizes scientific rigor, practical execution, and alignment with partner goals.
At the same time, Leveragen continues to expand its intellectual property estate around its core platform technologies, strengthening freedom to operate, long-term defensibility, and the strategic value of its discovery systems. Together, its platform breadth, integrated discovery engine, and growing patent portfolio position Leveragen as a durable innovation partner for next-generation biologics discovery and development.
Leveraging Genetics for Next-Generation Therapeutics
The name Leveragen reflects the company’s founding idea: creating leverage through enabling technology. It speaks to the ability to translate deep expertise in genetic engineering, antibody model development, and platform innovation into more efficient and more differentiated discovery outcomes for partners. Inspired in part by Archimedes and the principle of leverage, the name conveys the idea that a well-designed platform can amplify capability, extend reach, and unlock outsized impact. In that spirit, Leveragen was built to serve as a force multiplier for next-generation antibody discovery and therapeutic innovation.
Dr. Weisheng Chen, Founder, CEO, and Scientific Director of Leveragen, established the company to build next-generation in vivo platforms that expand what is possible in antibody discovery. A molecular geneticist turned entrepreneur, he has led Leveragen’s growth from its Boston base into a differentiated platform biotechnology company focused on advanced genetic engineering, integrated discovery, and translational impact. Dr. Chen earned his PhD in Cell, Developmental, and Neural Biology at the University of Michigan under the mentorship of Philippe Soriano and conducted postdoctoral research with Tom Maniatis at Harvard University and Columbia University. Prior to founding Leveragen in 2017, he was a Founding Scientist and Head of Genetic Models at Kallyope, Inc.
Careers
At Leveragen, we are committed to developing innovative solutions to address the most challenging medical problems. Our dedication to excellence drives us to push the boundaries of science and technology, achieving breakthroughs that transform lives and improve human health. We value collaboration and seek professionals from diverse backgrounds to join our dynamic team. By fostering an inclusive and innovative environment, we aim to make significant advancements in medical research and development. Join Leveragen to contribute to the future of healthcare and make a lasting impact.
